v3.25.1
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION
NOTE 15  - SEGMENT INFORMATION
 
The Company operates as a single operating segment in the research and development of innovative treatments for pancreatic cancer based on siRNAs. The Company’s CODM is its Chief Executive Officer (CEO). The CODM reviews the Company’s performance on a consolidated basis. As such, the segment’s loss is the Company’s consolidated net loss and the segment’s assets are the Company’s consolidated assets.
 
The CODM uses the information primarily to evaluate the Company’s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures, tracking progress on research and development milestones, and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows the CODM to monitor the Company's performance and make strategic adjustments as needed to support its operational and financial goals.
 
  a.
Segment disclosures
 
The CODM reviews the Company’s results on a consolidated basis. As such, information on segment loss and significant expenses is similar to the Company’s consolidated statements of operations. The CODM is also regularly provided with information on significant ordinary-course expenses, including the following expenses. the management does not segregate its business for internal reporting.
 
   
Year ended December 31
  
   
2024
    
2023
  
Clinical trials and other services from R&D-related service providers
  
$
1,893
    
$
2,480
  
Payroll and related expenses, other than share-based compensation
    
2,385
      
1,199
  
Share-based compensation expenses
    
5,862
      
130
  
Depreciation expenses
    
25
      
45
  
Other segment expenses (*)
    
2,406
      
827
  
Operating loss
    
12,571
      
4,681
  
Interest income
    
(28
)
    
(153
)

Interest expense

     27       -  
Other financing expense, net
    
3,939
      
548
  
Income taxes
    
10
      
32
  
Net loss
  
$
16,519
    
$
5,108
  
                 
Segment assets
  
$
2,863
    
$
5,256
  
Expenditures for segment assets
    
(22
)
    
(12
)
 
(*) Other segment expenses include mainly general and administrative-related expenses, such as payments to advisors and consultants, office lease expenses and maintenance, HR and legal expenses.
 
  b.
Entity-Wide disclosures
 
All of the Company’s long-lived assets are located in Israel.